For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Gastroparesis - Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gastroparesis Understanding
Gastroparesis: Overview
Gastroparesis is a disease in which the stomach cannot empty itself of food in a normal fashion. This is a common condition in people who have had diabetes for a long time, but it may also occur in other situations. Gastroparesis is caused by nerve injury, including damage to the vagus nerve. In its normal state, the vagus nerve contracts (tightens) the stomach muscles to help move food through the digestive tract. In cases of gastroparesis, the vagus nerve is damaged by diabetes. This prevents the muscles of the stomach and intestine from working properly, which keeps food from moving from the stomach to the intestines.
Symptoms
The
Symptoms of gastroparesis include:
- Heartburn or gastroesophageal reflux (backup of stomach contents into the esophagus)
- Nausea
- Vomiting undigested food
- Early satiety (feeling full quickly when eating)
- Abdominal bloating (enlargement)
- Poor appetite and weight loss
- Poor blood sugar control
Diagnosis
A
Diagnosis of gastroparesis is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Tests may first be performed to rule out other causes of delayed gastric emptying such as obstruction of the gastrointestinal tract. Additional tests are then performed to confirm a
Diagnosis of gastroparesis. An upper endosocpic procedure may lead to a serendipitous
Diagnosis of gastroparesis through the discovery of identifiable food within the stomach after the pre-procedure overnight fast.
Treatment
Treating the underlying cause of gastroparesis (such as tightening up blood glucose control in diabetes) is usually the first step in treating individuals with gastroparesis. The specific therapeutic techniques used depend upon several factors, including the severity of the disorder. Therapies that are used to treat individuals with gastroparesis include non-pharmacological steps, dietary modification, medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery. Medications that stimulate gastric emptying are called prokinetics. They are the primary
Treatment for individuals with gastroparesis. First-line medical
Treatment begins with the dopamine blockers. Of the two drugs, metoclopromide (Reglan) and domperidone (Motilitum), domperidone has a much better safety profile. Metoclopromide has serious neurological side effects, including irreversible tartive dyskinesia. Domperidone is now available in the United States through the FDA's Investigational New Drug protocol. Next are the motilin agonists, such as erythromycin.
Gastroparesis Emerging Drugs Chapters
This segment of the Gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastroparesis Emerging Drugs
- Tradipitant: Vanda Pharmaceuticals
Tradipitant is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.
- Relamorelin: AbbVie
Relamorelin is a Phase 2 ghrelin agonist in development for the
Treatment of diabetic gastroparesis and GI functional disorders. Derived from the natural ghrelin sequence, relamorelin has been optimized to stimulate gastrointestinal (GI) motility, with greater potency and enhanced stability and pharmacokinetics. Relamorelin has completed a Phase 2 trial in diabetic gastroparesis and a Phase 2a study in chronic constipation, and additional Phase 2 trials are under way in lower GI functional disorders and diabetic gastroparesis. The U.S. Food and Drug Administration (FDA) has granted Fast Track review status to relamorelin for the
Treatment of diabetic gastroparesis.
Further product details are provided in the report ..
Gastroparesis: Therapeutic Assessment
This segment of the report provides insights about the different Gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastroparesis
There are approx. 30+ key companies which are developing the therapies for Gastroparesis. The companies which have their Gastroparesis drug candidates in the most advanced stage, i.e. phase III include, AbbVie.
- Phases
DelveInsight's report covers around 30+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Gastroparesis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroparesis therapeutic drugs
Key Players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroparesis drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Gastroparesis.
- In May 2020, AbbVie announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
Gastroparesis Report Insights
- Gastroparesis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Gastroparesis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current
Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastroparesis drugs?
- How many Gastroparesis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the
Treatment of Gastroparesis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastroparesis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastroparesis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- RaQualia Pharma Inc.
- Vanda Pharmaceuticals
- Janssen Inc.
- UCB Pharma
- Tranzyme, Inc.
- Theravance Biopharma
- Targacept Inc.
- Takeda
- Merck Sharp & Dohme Corp.
- PTC Therapeutics
- Otsuka Pharmaceutical
- Neurogastrx, Inc.
- Motus Therapeutics, Inc.
- Millennium Pharmaceuticals
- Ironwood Pharmaceuticals, Inc.
- GlaxoSmithKline
- Forest Laboratories
- Evoke Pharma
- Eli Lilly and Company
- CinDome Pharma, Inc.
- Chugai Pharma USA
- Bird Rock Bio, Inc.
- Allergan
Key Products
- RQ-00000010
- Tradipitant
- Prucalopride
- Reglan ODT
- TZP-102
- Velusetrag
- TC-6499
- TAK-954
- Sitagliptin
- CNSA-001
- 13C-uracil
- NG101
- RM-131
- TAK-906
- IW-9179
- Camicinal
- Itopride
- Metoclopramide Nasal Spray
- tadalafil
- CIN-102
- GM-611
- Nimacimab
- Relamorelin